---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-048238"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:52:45.708427+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant: Phase 2 namilumab study fails in sarcoidosis; development discontinued

## Summary
- Namilumab failed to meet the primary endpoint (proportion of subjects with a Rescue Event) in chronic active pulmonary sarcoidosis.
- Secondary endpoints (FVC, corticosteroid tapering, King's Sarcoidosis Questionnaire) also showed no treatment benefit.
- Safety profile remained consistent with prior studies; no new safety signals emerged.
- Kinevant will discontinue further development of namilumab for sarcoidosis and plans to publish study results.
- Roivant CEO Matt Gline acknowledged the failure but highlighted other program successes and continued clinical risk-taking.

## SEC filing metadata
- accession: 0001140361-24-048238
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124048238/0001140361-24-048238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124048238/ef20039426_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-048238
- JSON: https://secwatch.observer/filing/0001140361-24-048238.json
- Plain text: https://secwatch.observer/filing/0001140361-24-048238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.